60470-82-8

Basic information

• Product Name: 5(4H)-Oxazolone, 4-[[4-(acetyloxy)-3-methoxyphenyl]methylene]-2-methyl-, (Z)-
• CAS NO: 60470-82-8
• Molecular Formula: C14H13NO5
• Molecular Weight: 275.261
• Mol File: 60470-82-8.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: 5(4H)-Oxazolone, 4-[[4-(acetyloxy)-3-methoxyphenyl]methylene]-2-methyl-, (Z)-(CAS DataBase Reference)
• NIST Chemistry Reference: 5(4H)-Oxazolone, 4-[[4-(acetyloxy)-3-methoxyphenyl]methylene]-2-methyl-, (Z)-(60470-82-8)
• EPA Substance Registry System: 5(4H)-Oxazolone, 4-[[4-(acetyloxy)-3-methoxyphenyl]methylene]-2-methyl-, (Z)-(60470-82-8)

Safety Data

• Hazardous Substances Data: 60470-82-8(Hazardous Substances Data)

Upstream product

• 24474-93-9 2-methyl-4H-oxazol-5-one 
• 881-68-5 vanillin acetate 
• 108-24-7 acetic anhydride 
• 121-33-5 vanillin 
• 543-24-8 N-acetylglycine 

Downstream Products

• 306-08-1 Homovanillic acid 
• 1081-71-6 3-(4-hydroxy-3-methoxyphenyl)-2-oxopropanoic acid 
• 7636-26-2 3-methoxy-DL-tyrosine 
• 100116-84-5 (2RS,3RS)-2-acetylamino-2-chloro-3-hydroxy-3-(4-hydroxy-3-methoxy-phenyl)-propionic acid 
• 108989-38-4 4-acetoxy-β-bromo-α-(2,2-dibromo-acetylamino)-3-methoxy-cinnamic acid 
• 32954-41-9 β-(3-methoxy-4-acetoxyphenyl)-α-acetamidoacrylic acid 
• 68706-13-8 S,S-m-methoxy-p-acetoxy-N-acetylphenylalanine α-phenylethylamide 
• 55739-56-5 α-acetamido-3-methoxy-4-acetoxycinnamic acid 
• 70723-30-7 (Z)-2-acetamido-3-(4-hydroxy-3-methoxyphenyl) acrylic acid 
• 59-92-7 levodopa 
• 63035-29-0 (Z)-2-Hydroxy-3-(4-hydroxy-3-methoxy-phenyl)-acrylic acid 
• 109442-89-9 4-(4-acetoxy-α-bromo-3-methoxy-benzylidene)-2-dibromomethyl-4H-oxazol-5-one 
• 106271-73-2 4-acetoxy-α-acetylamino-β-bromo-3-methoxy-cinnamic acid 
• 1384247-35-1 4-(4-hydroxy-3-methoxybenzylidene)-1-benzyl-2-methylimidazol-5-one 

Relevant articles and documents

Mechanistically Guided One Pot Synthesis of Phosphine-Phosphite and Its Implication in Asymmetric Hydrogenation

Although hybrid bidentate ligands are known to yield highly enantioselective products in asymmetric hydrogenation (AH), synthesis of these ligands is an arduous process. Herein, a one pot, atom-economic synthesis of a hybrid phosphine-phosphite (L1) is reported. After understanding the reactivity difference between an O-nucleophile versus C-nucleophile, one pot synthesis of Senphos (L1) was achieved (72 %). When L1 was treated with [Rh], 31P NMR revealed bidentate coordination to Rh. Senphos, in the presence of rhodium, catalyzes the AH of Methyl-2-acetamido-3-phenylacrylate and discloses an unprecedented turn over frequency of 2289, along with excellent enantio-selectivity (92 %). The generality is demonstrated by hydrogenating an array of alkenes. The AH operates under mild conditions of 1–2 bar H2 pressure, at room temperature. The practical relevance of L1 is demonstrated by scaling-up the reaction to 1 g and by synthesizing DOPA, a drug widely employed for the treatment of Parkinson's disease. Computational insights indicate that the R isomer is preferred by 3.8 kcal/mol over the S isomer.

NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR

Provided are a novel compound having skin-whitening, anti-oxidizing and PPAR activities and a medical use thereof, and the compound has skin-whitening activities for the suppression of tyrosinase, and accordingly, is useful for use in skin-whitening pharmaceutical composition or cosmetic products; has anti-oxidant activities, and accordingly, is useful for the prevention and treatment of skin-aging; and has PPAR activities, and in particular, PPARα and PPARγ activities, and accordingly, is useful for use in pharmaceutical compositions or health foods which are effective for the prevention and treatment of obesity, metabolic disease, or cardiovascular disease.

SUBSTITUTED BETA-PHENYL-ALPHA-HYDROXY PROPANOIC ACID, SYNTHESIS METHOD AND USE THEREOF

The present invention relates to a compound of the formula (I), wherein R1, R2 and R3 are each independently selected from H, OH, F, Cl, Br, methoxy and ethoxy; or alternatively, R1 and R2 together form -OCH2O-, R3 is selected from H, OH, methoxy, ethoxy and halogens; R4 is OH or acyloxy; R5 is cycloalkoxyl, amino and substituted amino, and when R5 is selected from amino, at least one of R1, R2 and R3 is not H. The present invention further relates to a process for synthesizing a compound of the formula (I), and use of the compound of the formula (I) in the manufacture of a medicament for the prevention or treatment of cardiovascular or cerebrovascular diseases.